...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Ribonuclease-resistant RNA Controls (Armored RNA) for Reverse Transcription-PCR, Branched DNA, and Genotyping Assays for Hepatitis C Virus
【24h】

Ribonuclease-resistant RNA Controls (Armored RNA) for Reverse Transcription-PCR, Branched DNA, and Genotyping Assays for Hepatitis C Virus

机译:抗核糖核酸酶的RNA对照(装甲RNA)用于逆转录PCR,支链DNA和丙型肝炎病毒基因分型分析

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Comparison and evaluation of molecular diagnostic assays for the detection and quantification of hepatitis C virus (HCV) RNA have been limited by the lack of RNA controls and calibrators. Armored RNA? technology is a means for producing RNA that is completely protected from plasma ribonucleases. This method produces recombinant pseudoviral particles that are noninfectious and contain predefined RNA sequences.Methods: A consensus 412-base sequence from the 5′NCR/Core region of HCV subtype 2b was derived from 34 individually sequenced HCV genotype 2b variants. A DNA fragment encoding the consensus HCV-2b sequence was synthesized de novo, cloned, and expressed as an Armored RNA control. The resulting HCV-2b Armored RNA (AR-HCV-2b) contained the complete HCV-2b consensus RNA sequence encapsidated within a protective protein coat.Results: AR-HCV-2b was fully recoverable from human plasma incubated at 4 °C for 300 days. The particles were tested in three clinical assay formats: AmplicorTM HCV Monitor 1.0, QuantiplexTM HCV RNA 2.0, and INNO-LiPATM HCV II. When added into seronegative, nonviremic plasma, AR-HCV-2b showed reproducible signals and linear dilutions in both the Amplicor and Quantiplex assays. AR-HCV-2b was correctly identified as subtype 2b in the INNO-LiPA line probe assay.Conclusion: The HCV-2b Armored RNA control is a versatile, durable, ribonuclease-resistant viral RNA control that is compatible in three different clinical assay formats.
机译:背景:由于缺乏RNA对照和校准剂,用于检测和定量丙型肝炎病毒(HCV)RNA的分子诊断分析方法的比较和评估受到限制。装甲RNA?这项技术是一种生产完全不受血浆核糖核酸保护的RNA的方法。该方法产生非感染性且含有预定RNA序列的重组伪病毒颗粒。方法:来自34个单独测序的HCV基因型2b变体的HCV亚型2b的5'NCR / Core区域的共有412个碱基的序列。从头合成了编码共有HCV-2b序列的DNA片段,将其克隆并表达为装甲RNA对照。产生的HCV-2b装甲RNA(AR-HCV-2b)包含完整的HCV-2b共有RNA序列,包裹在保护性蛋白外壳中。结果:AR-HCV-2b可以从在4°C下孵育>的人血浆中完全回收。 300天以三种临床测定形式测试了颗粒:AmplicorTM HCV Monitor 1.0,QuantiplexTM HCV RNA 2.0和INNO-LiPATM HCV II。当添加到血清阴性,非病毒血症血浆中时,AR-HCV-2b在Amplicor和Quantiplex分析中均显示出可重现的信号和线性稀释度。结论:HCV-2b装甲RNA对照是一种多功能,耐用,耐核糖核酸酶的病毒RNA对照,可在三种不同的临床检测格式中兼容,因此AR-HCV-2b在INNO-LiPA线探针检测中被正确鉴定为2b亚型。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号